78亿美元!一细胞治疗公司被收购

生物科技馆
Feb 24

2026年2月23日,全球生物制药巨头吉利德科学公司(纳斯达克代码:GILD)宣布与临床阶段生物技术公司Arcellx(纳斯达克代码:ACLX)达成最终收购协议,拟以78亿美元的隐含股权价值将其纳入麾下,此举旨在全面掌控Arcellx核心CAR-T管线Anito-cel,进一步巩固吉利德在肿瘤免疫治疗领域的竞争力,尤其聚焦多发性骨髓瘤治疗赛道的布局深化。吉利德公司Kite和Arcellx现有合作,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10